Cellerant Therapeutics

Cellerant awarded $47.5M for development of CLT-008 for acute radiation syndrome

Friday, September 12, 2014

Cellerant Therapeutics, a California biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the office of the assistant secretary for preparedness and response of the department of Health and Human Services.

[Read More]

Court recognizes majority of Viropro shareholders’ election of new board of directors

Friday, June 6, 2014

Viropro, a Nevada corporation that was formed to specialize in contract research, development and manufacturing of biotherapeutic proteins for including cancer, diabetes, inflammation and hepatitis, has a new board of directors as a result of an order of the Supreme Court of the State of New York in a challenge by a majority of the Viropro shareholders to the management of Viropro.

[Read More]

Cellerant awarded $36.4M to develop CLT-008 for acute radiation syndrome

Thursday, September 6, 2012

Cellerant Therapeutics, a biotech developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has been awarded $36.4 million under an option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the office of the assistant secretary for preparedness and response of the Department of Health and Human Services, for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of acute radiation syndrome (ARS).

[Read More]